In a phase 3 clinical trial, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

Orforglipron carried more side effects, however ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist pill is more effective for weight loss than oral semaglutide in patients with Type 2 diabetes, a 2026 Phase III trial ...

USA: Oral semaglutide may lower the risk of heart failure-related events in people with type 2 diabetes who already have heart failure, without increasing serious adverse events, a secondary analysis ...

One of semaglutide's inactive ingredients has been linked to changes in gut bacteria and inflammatory markers. | Drug Discovery And Development ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had ...

Downside to dropping pounds? The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side ...